Acerta Pharma - Articles and news items

Orphan drug designation recommended for acalabrutinib in three indications

Industry news / 25 February 2016 / Victoria White

The COMP has recommended the orphan drug designation for acalabrutinib in chronic lymphocytic leukaemia, mantle cell lymphoma and lymphoplasmacytic lymphoma…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+